CLRB Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals has a net margin of -- compared to Cellectar Biosciences's net margin of -104.98%. Cellectar Biosciences's return on equity of -- beat Ionis Pharmaceuticals's return on equity of -93.21%.

Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 2135.37%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 67.97%. Given that Cellectar Biosciences has higher upside potential than Ionis Pharmaceuticals, analysts believe Cellectar Biosciences is more attractive than Ionis Pharmaceuticals.

Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Cellectar Biosciences quarterly revenues are --, which are smaller than Ionis Pharmaceuticals quarterly revenues of $133.8M. Cellectar Biosciences's net income of -$14.7M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus 6.64x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals has a net margin of -- compared to Cellectar Biosciences's net margin of -13.84%. Cellectar Biosciences's return on equity of -- beat Ligand Pharmaceuticals's return on equity of 5.97%.

Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 2135.37%. On the other hand Ligand Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 27.01%. Given that Cellectar Biosciences has higher upside potential than Ligand Pharmaceuticals, analysts believe Cellectar Biosciences is more attractive than Ligand Pharmaceuticals.

Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Ligand Pharmaceuticals has a beta of 1.038, suggesting its more volatile than the S&P 500 by 3.81%.

Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Ligand Pharmaceuticals pays out -- of its earnings as a dividend.

Cellectar Biosciences quarterly revenues are --, which are smaller than Ligand Pharmaceuticals quarterly revenues of $51.8M. Cellectar Biosciences's net income of -$14.7M is lower than Ligand Pharmaceuticals's net income of -$7.2M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Ligand Pharmaceuticals's PE ratio is 45.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus 13.44x for Ligand Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to Cellectar Biosciences's net margin of -63.65%. Cellectar Biosciences's return on equity of -- beat Revance Therapeutics's return on equity of --.

Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 2135.37%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 147.96%. Given that Cellectar Biosciences has higher upside potential than Revance Therapeutics, analysts believe Cellectar Biosciences is more attractive than Revance Therapeutics.

Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Cellectar Biosciences quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Cellectar Biosciences's net income of -$14.7M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus 1.16x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks has a net margin of -- compared to Cellectar Biosciences's net margin of -186.56%. Cellectar Biosciences's return on equity of -- beat Zymeworks's return on equity of -27.06%.

Cellectar Biosciences has a consensus price target of $5.67, signalling upside risk potential of 2135.37%. On the other hand Zymeworks has an analysts' consensus of $19.86 which suggests that it could grow by 40.42%. Given that Cellectar Biosciences has higher upside potential than Zymeworks, analysts believe Cellectar Biosciences is more attractive than Zymeworks.

Cellectar Biosciences has a beta of 0.891, which suggesting that the stock is 10.942% less volatile than S&P 500. In comparison Zymeworks has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.109%.

Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

Cellectar Biosciences quarterly revenues are --, which are smaller than Zymeworks quarterly revenues of $16M. Cellectar Biosciences's net income of -$14.7M is higher than Zymeworks's net income of -$29.9M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 657.46x versus 17.03x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.